Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma

Hisakazu Nishimori, Nobuharu Fujii, Yoshinobu Maeda, Ken Ichi Matsuoka, Katsuto Takenaka, Katsuji Shinagawa, Kazuma Ikeda, Keitaro Matsuo, Mine Harada, Mitsune Tanimoto

Research output: Contribution to journalArticle


Background: The effects of a novel salvage regimen, IDEA (ifosfamide, cytosine arabinoside, etoposide and dexamethasone), which does not include anthracycline or platinum, in patients with non-Hodgkin's lymphoma (NHL) were examined. Patients and Methods: Thirty-four patients with refractory or relapsed NHL were treated with IDEA. Results: The overall remission and complete remission rates were 67.6% and 35.3%, respectively. The toxicity of IDEA was tolerable. With a median follow-up of 14 months, one-year overall survival (OS) and progression-free survival rates were 75.1% and 43.7%, respectively. Adequate numbers of CD34+ cells were obtained in 77.8% of the patients assigned to receive autologous peripheral blood stem cell (PBSC) transplantation. High-dose chemotherapy with autologous PBSC transplantation was carried out in 14 patients; their 3-year OS was 75.0%, with a median follow-up of 38 months. Conclusion: IDEA is an effective secondline chemotherapy regimen for NHL patients and has an excellent PBSC-mobilizing effect.

Original languageEnglish
Pages (from-to)1749-1754
Number of pages6
JournalAnticancer research
Issue number5
Publication statusPublished - May 1 2009


All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Nishimori, H., Fujii, N., Maeda, Y., Matsuoka, K. I., Takenaka, K., Shinagawa, K., ... Tanimoto, M. (2009). Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma. Anticancer research, 29(5), 1749-1754.